Business
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b
About this update from Vera Therapeutics, Inc.
[{"type":"text","content":"Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept’s potential as long-term disease-modifying IgAN therapy Atacicept showed continued protective titers to diphtheria and tetanus and balanced COVID infections vs. placebo in IgAN BRISBANE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that three abstracts on the Company’s product candidate atacicept in immunoglobulin A nephropathy (IgAN) have been selected for poster presentations at the American Society of Nephrology (ASN) Kidney Week 2023, which is taking place November 2–5, 2023, in Philadelphia, PA. Kidney Week Poster Presentation Details:Poster Title:ORIGIN 3: Pivotal Ph3 Study Evaluating Effect of Atacicept vs Placebo on Proteinuria and Renal Function Preservation in IgANPresenting Author:Jonathan Barratt, Ph.D., FRCP, The Mayer Professor of Renal Medicine, University of Leicester, UKPoster #:INFO17-THSession Date, Time:Thursday November 2, 2023 from 10:00 AM to 12:00 PM ET Poster Title:Atacicept 150mg Reduces Serum Gd-IgA1, a Biomarker Associated with Long-term Outcomes in IgAN: 36W Results from the Ph2b ORIGIN StudyPresenting Author:Jonathan Barratt, Ph.D., FRCP, The Mayer Professor of Renal Medicine, University of Leicester, UKPoster #:SA-PO887Session Title:Glomerular Diseases: Therapeutics [PO1402-1]Session Date, Time:Saturday November 4, 2023 from 10:00 AM to 12:00 PM ET Poster Title:Atacicept in IgAN: Continued Protective Titers to Diphtheria and Tetanus and Balanced Infections vs Placebo with a Focus on COVID-19Presenting Author:Jonathan Barratt, Ph.D., FRCP, The Mayer Professor of Renal Medicine, University of Leicester, UKPoster #:SA-PO884Session Title:Glomerular Diseases: Therapeutics [PO1402-1]Session Date, Time:Saturday November 4, 2023 from 10:00 AM to 12:00 PM ET For more information on these abstracts, please visit the ASN Kidney Week 2023 website. About AtaciceptAtacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and...